GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...

Caroline Igo (she/her/hers) is a wellness editor and holds Sleep Science Coach and Stress Management certificates from the Spencer Institute. She received her bachelor's degree in creative writing ...

Therapeutic Use Exemption (TUE) Physician Guidelines - on Asthma. All TUE Physician Guidelines are reviewed annually by WADA's TUE Expert Advisory Group to ensure that they remain consistent with good ...

GlaxoSmithKline (GSK) is on course for US approval of its mepolizumab candidate after an FDA advisory committee voted unanimously in favour of its use in adults with severe asthma.

Both assets are poised to enter registrational studies under accelerated approval pathways, according to Jefferies. GSK to Stay Out of Obesity—but not GLP-1s At JPM25 on Monday, GSK Chief Scientific ...

GSK plc GSK expects strong momentum in the specialty business segment to continue with growth from existing assets. At the JPMorgan Healthcare Conference, the European healthcare giant noted there ...

Following GSK’s deal-heavy end to 2024, Chief Scientific Officer Tony Wood, Ph.D., doesn’t expect the trend to let up in the new year, zeroing in on partnerships that can expand knowledge ...

Responsible of the Severe Asthma Unit and Chronic Cough Unit, Corporació Sanitària Universitària Parc Taulí; Professor of Medicine, Department of Medicine, Universitat Autònoma de Barcelona (UAB), ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Eli Lilly made a $2.5 billion deal for a breast cancer drug; GSK reached a $1 billion-plus deal for IDRx. The announcements suggest a potential rebound in M&A deals in the healthcare sector for 2025.

but precisely pinpointing asthma endotype has relied on an invasive procedure that can be difficult to perform on a child. (Blakemore, 1/12) Stat: GSK To Buy IDRx For $1B, Picking Up GI Cancer Drug ...

GSK has agreed to buy US biopharmaceutical business IDRx in a deal worth up to $1.15billion (£1billion). Under the agreement, GSK will pay $1billion upfront to acquire the Massachusetts-based ...